High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy.

Abstract

We treated 2 patients with IgM monoclonal paraproteinemic demyelinating peripheral neuropathy (PPN) with monthly intravenous human immunoglobulin. Both patients had a steadily progressive course in spite of steroid and other immunosuppressive therapy for 3 years before starting the immunoglobulin therapy. Both had a rapid clinical improvement noticeable 5 to 10 days after the 1st immunoglobulin infusion lasting on the average of 3 to 6 weeks. Retreatment caused improvement after each consecutive infusion. There were no significant adverse side effects. High-dose IV human immunoglobulin can be a useful therapy in the treatment of PPN and warrants a large-scale controlled therapeutic trial.

• Authors: D Cook, M Dalakas, A Galdi, D Biondi, H Porter
• Journal: Neurology (Neurology) Vol. 40 Issue 2 Pg. 212-4 (Feb 1990) ISSN: 0028-3878 [Print] United States
• PMID: 2153942 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunoglobulins

Topics

• Aged
• Demyelinating Diseases (therapy)
• Humans
• Immunization, Passive
• Immunoglobulins (administration & dosage)
• Infusions, Intravenous
• Male
• Paraproteinemias (therapy)
• Peripheral Nervous System Diseases (therapy)